PMID- 32318530
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki 
      Disease.
PG  - 148
LID - 10.3389/fped.2020.00148 [doi]
LID - 148
AB  - Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line 
      treatment for Kawasaki disease (KD); however, 10-20% of patients fail to respond 
      and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for 
      macrophage activation. There are no reports measuring serum sCD163 in KD 
      patients. This study aimed to explore its possible utility in the clinical 
      management of patients with KD. Methods: Eighty-seven patients with well-defined 
      KD were retrospectively enrolled together with 19 healthy individuals with 
      comparable ages. KD patients were classified into three groups, Group A (initial 
      IVIG responders), Group B (additional IVIG responders), and Group C (additional 
      IVIG non-responders). Serum sCD163 together with complete blood counts, 
      C-reactive protein, d-dimer, albumin, aspartate aminotransferase (AST), and 
      alanine aminotransferase (ALT) were measured before the initial IVIG treatment in 
      all cases, and afterward in a fraction of cases. Results: Serum sCD163 in KD 
      patients before initial IVIG was generally much higher than the control group. 
      The median (interquartile range) of sCD163 was as follows: Control 446 (385-521) 
      ng/mL; Group A, 699 (478-1,072); Group B, 1,349 (1,116-1,390); and Group C, 665 
      (544-1,094). In general, sCD163 showed close positive correlation with ALT and 
      AST, but none with other markers. Among the KD groups, Group B showed the highest 
      sCD163: Group B vs. A: p = 0.0003; B vs. C: p = 0.035). Serum sCD163 was 
      significantly increased after IVIG in Group A, while no change occurred in 
      others. Conclusion: The serum sCD163 levels could be a useful biomarker in the 
      clinical management of KD, especially for predicting responsiveness to IVIG.
CI  - Copyright (c) 2020 Azuma, Suzuki, Okada, Matsuguma, Wakiguchi, Ohnishi, Furuta, 
      Miyake, Yasudo, Ichihara, Ohga and Hasegawa.
FAU - Azuma, Yoshihiro
AU  - Azuma Y
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Suzuki, Yasuo
AU  - Suzuki Y
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Okada, Seigo
AU  - Okada S
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Matsuguma, Chie
AU  - Matsuguma C
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Wakiguchi, Hiroyuki
AU  - Wakiguchi H
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Ohnishi, Yuji
AU  - Ohnishi Y
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Furuta, Takashi
AU  - Furuta T
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Miyake, Akiko
AU  - Miyake A
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Yasudo, Hiroki
AU  - Yasudo H
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
FAU - Ichihara, Kiyoshi
AU  - Ichihara K
AD  - Department of Laboratory Sciences, Faculty of Health Sciences, Yamaguchi 
      University Graduate School of Medicine, Ube, Japan.
FAU - Ohga, Shouichi
AU  - Ohga S
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
AD  - Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 
      Fukuoka, Japan.
FAU - Hasegawa, Shunji
AU  - Hasegawa S
AD  - Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7154120
OTO - NOTNLM
OT  - Kawasaki disease
OT  - intravenous immunoglobulin
OT  - macrophage
OT  - sCD163
OT  - soluble CD163
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
PMCR- 2020/04/07
CRDT- 2020/04/23 06:00
PHST- 2019/09/13 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
PHST- 2020/04/07 00:00 [pmc-release]
AID - 10.3389/fped.2020.00148 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Apr 7;8:148. doi: 10.3389/fped.2020.00148. eCollection 2020.